Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 25Recruiting 11Terminated 7Unknown 4Active not recruiting 3Withdrawn 2Enrolling by invitation 2Suspended 1Approved for marketing 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 46Gastrointestinal 8Gynecologic 4Genitourinary 4Thoracic 3Sarcoma 2Head & Neck 2Plasma cell 1NET 1Endocrine 1Dermatologic 1CNS 1

Conditions

Carcinoma, Neuroendocrine 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Sarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasms 1Mesothelioma, Malignant 1Melanoma 1Hodgkin Disease 1Gallbladder Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

tivozanib 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Breast Neoplasms × Endocrine × Clear all
NCT05000294 2026-02-18

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

University of Florida

Phase 1/2 Suspended
29 enrolled
BreastEndocrineGastrointestinalGenitourinaryGynecologicNETSarcoma

Bile Duct Neoplasms, Breast Neoplasms, Gallbladder Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Vulvar Neoplasms, Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡